ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1

Background. Acute rejection (AR) associated with de novo production of donor-specific antibodies (DSA) is a clinicopathological entity that carries a poor prognosis (acute humoral rejection, AHR). The aim of this study was to determine the incidence and clinical characteristics of AHR in renal allograft recipients, and to further analyze the antibodies involved. Methods. During a 4-year period, 232 renal transplants (Tx) were performed at our institution. Assays for DSA included T and B cell cytotoxic and/or flow cytometric cross-matches and cytotoxic antibody screens (PRA). C4d complement staining was performed on frozen biopsy tissue. Results. A total of 81 patients (35%) suffered at least one episode of AR within the first 3 months: 51 had steroid-insensitive AR whereas the remaining 30 had steroid-sensitive AR. No DSA were found in patients with steroid-sensitive AR. In contrast, circulating DSA were found in 19/51 patients (37%) with steroid-insensitive AR, and widespread C4d deposits in peritubular capillaries were present in 18 of these 19 (95%). In at least three cases, antibodies were against donor HLA class II antigens. DSA were not found in the remaining 32 patients but C4d staining was positive in 2 of 32. The DSA/C4d positive (n=18) and DSA/C4d negative (n=30) groups differed in pre-Tx PRA levels, percentage of re-Tx patients, refractoriness to antilymphocyte therapy, and outcome. Plasmapheresis and tacrolimus-mycophenolate mofetil rescue reversed rejection in 9 of 10 recipients with refractory AHR. Conclusion. More than one-third of the patients with steroid-insensitive AR had evidence of AHR, often resistant to antilymphocyte therapy. Most cases (95%) with DSA at the time of rejection had widespread C4d deposits in peritubular capillaries, suggesting a pathogenic role of the circulating alloantibody. Combined DSA testing and C4d staining provides a useful approach for the early diagnosis of AHR, a condition that often necessitates a more intensive therapeutic rescue regimen.

[1]  D. Riley,et al.  Shared cadaver donor-husband HLA class I mismatches as a risk factor for renal graft rejection in previously pregnant women. , 1999, Human immunology.

[2]  R. Colvin,et al.  Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. , 1999, Journal of the American Society of Nephrology : JASN.

[3]  F. Delmonico,et al.  Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. , 1999, Transplantation.

[4]  W. Baldwin,et al.  Complement causes allograft injury by cell activation rather than lysis. , 1999, Transplantation.

[5]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[6]  R. Colvin,et al.  Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. , 1998, Transplantation.

[7]  M. Fishbein,et al.  Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. , 1998, Transplantation.

[8]  J. Kalil,et al.  Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. , 1998, Human immunology.

[9]  B. Burke,et al.  Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. , 1997, Journal of the American Society of Nephrology : JASN.

[10]  H. Lang,et al.  Flow cytometry cross-match: a method for predicting graft rejection. , 1997, Transplantation.

[11]  R. Colvin.  The renal allograft biopsy. , 1996, Kidney international.

[12]  P. Halloran,et al.  Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. , 1996, Transplantation.

[13]  W. Land,et al.  Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. , 1996, Transplantation.

[14]  M. Pescovitz,et al.  Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. , 1995, Transplantation.

[15]  P. Halloran,et al.  Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. , 1995, Transplantation.

[16]  T. Pruett,et al.  EVIDENCE DEMONSTRATING POOR KIDNEY GRAFT SURVIVAL WHEN ACUTE REJECTIONS ARE ASSOCIATED WITH IgG DONOR‐SPECIFIC LYMPHOCYTOTOXIN , 1995, Transplantation.

[17]  W. Baldwin,et al.  The Contribution Of Terminal Complement Components To Acute And Hyperacute Allograft Rejection In The Rat , 1995, Transplantation.

[18]  F. Delmonico,et al.  Second renal transplantations. Ethical issues clarified by outcome; outcome enhanced by a reliable crossmatch. , 1994, Archives of surgery.

[19]  P. Halloran,et al.  THE SIGNIFICANCE OF THE ANTI–CLASS I RESPONSE , 1992, Transplantation.

[20]  G. Riethmüller,et al.  Vascular deposition of complement‐split products in kidney allografts with cell‐mediated rejection , 1991, Clinical and experimental immunology.

[21]  P. Stastny,et al.  Alloantibodies against donor epidermis and early kidney transplant rejection. , 1991, Transplantation.

[22]  R. Howard,et al.  Posttransplant antidonor antibodies and graft rejection. Evaluation by two-color flow cytometry. , 1989, Transplantation.

[23]  U. Hopt,et al.  The development of a positive donor-specific cross-match after kidney transplantation is detrimental to the graft. , 1989, Transplantation proceedings.

[24]  R. Gokal,et al.  Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. , 1987, Transplantation.

[25]  W. Baldwin,et al.  Vascular endothelial alloantigens in renal transplantation. , 1985, Transplantation.

[26]  L. Brasile,et al.  THE VASCULAR ENDOTHELIAL CELL ANTIGEN SYSTEM , 1985, Transplantation.

[27]  D. Phelan,et al.  ANTIGENIC SPECIFICITY OF ANTIBODY REACTIVE IN THE ANTIGLOBULIN‐AUGMENTED LYMPHOCYTOTOXICITY TEST , 1982, Transplantation.

[28]  H. Winn,et al.  ACUTE DESTRUCTION BY HUMORAL ANTIBODY OF RAT SKIN GRAFTED TO MICE , 1973, The Journal of experimental medicine.

[29]  H. Kreis,et al.  [Second renal transplantations]. , 1972, La Nouvelle presse medicale.

[30]  D. Fitzpatrick.  A simple method for removal of OKT3 from patient sera. , 1996 .

[31]  P. Halloran,et al.  The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. , 1990, Transplantation.